Bayer competitors and similar companiesClear all

Bayer's competitors and similar companies include Shionogi, Astellas Pharma, AstraZeneca, Roche, Novartis, Pfizer, GSK and Johnson & Johnson.
Bayer
Bayer
Bayer is a global life science company specializing in healthcare and nutrition.
Shionogi
Shionogi
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
Astellas Pharma
Astellas Pharma
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Roche
Roche
Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
GSK
GSK
GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
Founding Date
Founding Date
1863
Founding Date
1878
Founding Date
1923
Founding Date
1999
Founding Date
1896
Founding Date
1996
Founding Date
1849
Founding Date
2000
Founding Date
1886
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Leverkusen, DE HQ
Tirana, AL
Dely Ibrahim, DZ
Luanda, AO
Munro, AR
Pymble, AU
Wien, AT
see more
Locations
Osaka, JP HQ
Beijing, CN
Hong Kong, HK
Amagasaki, JP
Amagasaki, JP
Kanegasaki, JP
Misato, JP
see more
Locations
Tokyo, JP HQ
Macquarie Park, AU
Wien, AT
Vilvoorde, BE
São Paulo, BR
Markham, CA
Beijing, CN
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Dhaka, BD
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Footscray, AU
Mulgrave, AU
Sydney, AU
see more
Locations
Brentford, GB HQ
Boumerdes, DZ
San Fernando, AR
Abbotsford, AU
Ermington, AU
Wien, AT
Minsk, BY
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Chippendale, AU
Wien, AT
Minsk, BY
Beerse, BE
Brussel, BE
see more
Employees
Employees
101,9141% increase
Employees
5,6934% increase
Employees
15,4553% decrease
Employees
76,1008% increase
Employees
100,9201% decrease
Employees
104,3231% decrease
Employees
79,0001% increase
Employees
90,0964% decrease
Employees
141,7005% increase
Valuation ($)
Valuation ($)
56.8 b
Valuation ($)
15 b
Valuation ($)
28.3 b
Valuation ($)
212.9 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
286.7 b
Valuation ($)
70.8 b
Valuation ($)
467.3 b
Twitter followers
Twitter followers
184.6 k
Twitter followers
N/A
Twitter followers
50.4 k
Twitter followers
303.1 k
Twitter followers
246.6 k
Twitter followers
302.4 k
Twitter followers
32 k
Twitter followers
241.1 k
Twitter followers
249.5 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
53
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
25
Number of tweets (last 30 days)
36
Number of tweets (last 30 days)
44
Number of tweets (last 30 days)
12
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
51
Number of tweets (last 30 days)
22
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
11.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
5.8
Average likes per tweet (last 30 days)
11.9
Average likes per tweet (last 30 days)
7.6
Average likes per tweet (last 30 days)
4.8
Average likes per tweet (last 30 days)
17.5
Average likes per tweet (last 30 days)
15.9
Average likes per tweet (last 30 days)
7
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
49.06%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
96%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
90.91%
Percentage of tweets with engagement (last 30 days)
50%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
92.16%
Percentage of tweets with engagement (last 30 days)
54.55%
Alexa Website Rank
Alexa Website Rank
105500
Alexa Website Rank
286002
Alexa Website Rank
330601
Alexa Website Rank
71159
Alexa Website Rank
46160
Alexa Website Rank
129099
Alexa Website Rank
33980
Alexa Website Rank
23804
Alexa Website Rank
17146
Employee Rating
Employee Rating
4.3
Employee Rating
3.6
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
€44.1b (FY, 2021)
Revenue (est.)
¥335.1b (FY, 2022)
Revenue (est.)
¥1.3t (FY, 2022)
Revenue (est.)
$37.4b (FY, 2021)
Revenue (est.)
CHF62.8b (FY, 2021)
Revenue (est.)
$52.9b (FY, 2021)
Revenue (est.)
$81.3b (FY, 2021)
Revenue (est.)
£34.1b (FY, 2021)
Revenue (est.)
$93.8b (FY, 2021)
Cost of goods
Cost of goods
(€11.7b) (FY, 2021)
Cost of goods
¥43b (FY, 2022)
Cost of goods
¥173.3b (FY, 2022)
Cost of goods
$5.9b (FY, 2021)
Cost of goods
(CHF15.5b) (FY, 2021)
Cost of goods
$9.7b (FY, 2021)
Cost of goods
$30.8b (FY, 2021)
Cost of goods
£11.6b (FY, 2021)
Cost of goods
$29.9b (FY, 2021)
Gross profit
Gross profit
€33.6b (FY, 2021)
Gross profit
¥294b (FY, 2022)
Gross profit
¥1.2t (FY, 2022)
Gross profit
$32b (FY, 2021)
Gross profit
CHF50.4b (FY, 2021)
Gross profit
$45.1b (FY, 2021)
Gross profit
$50.5b (FY, 2021)
Gross profit
£22.5b (FY, 2021)
Gross profit
$63.9b (FY, 2021)
Net income
Net income
€1b (FY, 2021)
Net income
¥113.4b (FY, 2022)
Net income
¥124.1b (FY, 2022)
Net income
$115m (FY, 2021)
Net income
CHF14.9b (FY, 2021)
Net income
$24b (FY, 2021)
Net income
$22b (FY, 2021)
Net income
£5.1b (FY, 2021)
Net income
$20.9b (FY, 2021)

Operating

Countries
Countries
83 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
130 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
125 (FY, 2021)
Countries
92 (FY, 2021)
Countries
N/A
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
4 (FY, 2018)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
85 (FY, 2021)
Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
39 (FY, 2021)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
27 (FY, 2021)
Phase I Trials Products
16 (FY, 2021)
Phase I Trials Products
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
1 (Oct, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
4 (Jan, 2022)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
1 (FY, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
36 (Jan, 2022)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Other)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
3 (Oct, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
2 (Jan, 2022)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
25 (FY, 2021)
Phase II Trials Products
6 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
1 (Oct, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (Jan, 2022)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
1 (FY, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
11 (Jan, 2022)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
2 (Oct, 2020)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
3 (Jan, 2022)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
54 (FY, 2021)
Phase III Trials Products
27 (FY, 2021)
Phase III Trials Products
11 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
1 (Oct, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
7 (Jan, 2022)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
4 (Oct, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (Jan, 2022)
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Other)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Oct, 2020)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Jan, 2022)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Registration Phase Products
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
8 (FY, 2021)
Registration Phase Products
10 (FY, 2021)
Registration Phase Products
N/A
Registration Phase Products
N/A
Suppliers
Suppliers
93.8 k (FY, 2021)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
37.5 k (FY, 2021)
Suppliers
N/A
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
4 (FY, 2020)
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
$ 3.5b
Total funding raised
$ 4.7m
Total funding raised
N/A
Total funding raised
$ 1b
Total funding raised
$ 7.8b
Total funding raised
$ 6.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Shionogi
HQ
Osaka, JP
Employees
5,693↑ 4% increase

Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.

View company
Astellas Pharma
HQ
Tokyo, JP
Employees
15,455↓ 3% decrease

Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.

View company
AstraZeneca
HQ
Cambridge, GB
Employees
76,100↑ 8% increase

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.

View company
Roche
HQ
Basel, CH
Employees
100,920↓ 1% decrease

Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.

View company